Bracht Karin, Neumann Christian, Grünert Renate, Bednarski Patrick J
Department of Medicinal/Pharmaceutical Chemistry, Institute of Pharmacy, University of Greifswald, Germany.
Arch Pharm (Weinheim). 2004 Dec;337(12):668-71. doi: 10.1002/ardp.200400620.
Increases in the intracellular levels of glutathione (GSH) in cancer cells have been implicated in the development of acquired resistance to platinum antitumor agents. On the other hand, little information is available on the relationships between intracellular GSH levels in non-treated cancer cells and their response to platinum complexes. The present work investigated for possible correlations between concentrations of intracellular GSH/GSSG in 14 human cancer cell lines growing in vitro and the cell growth inhibitory activities of cisplatin, carboplatin, oxaliplatin, and d,l-trans-1,2-diaminocyclohexane-dichloro-platinum(II) (DACH-Pt). No statistically significant correlation between GSH levels and the activities of any of the four Pt-complexes could be found.
癌细胞内谷胱甘肽(GSH)水平的升高与获得性铂类抗肿瘤药物耐药性的发展有关。另一方面,关于未处理癌细胞内GSH水平与其对铂配合物反应之间的关系,目前所知甚少。本研究调查了14种体外培养的人癌细胞系中细胞内GSH/GSSG浓度与顺铂、卡铂、奥沙利铂和d,l-反式-1,2-二氨基环己烷-二氯铂(II)(DACH-Pt)的细胞生长抑制活性之间的可能相关性。未发现GSH水平与四种铂配合物中任何一种的活性之间存在统计学上的显著相关性。